Please try another search
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer’s disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Name | Age | Since | Title |
---|---|---|---|
Arnon Rosenthal | 67 | 2013 | Co-Founder, CEO & Director |
David M. Wehner | 54 | 2018 | Independent Director |
Kristine Yaffe | 60 | 2019 | Independent Director |
Elizabeth A. Garofalo | 65 | 2021 | Independent Director |
Louis J. Lavigne | 74 | 2018 | Independent Chairperson of the Board |
Richard H. Scheller | 71 | 2018 | Director & Member of Scientific Advisory Board |
Stephen L. Hauser | - | - | Member of Scientific Advisory Board |
Adam L. Boxer | - | - | Member of Scientific Advisory Board |
Michael Heneka | - | - | Member of Scientific Advisory Board |
Paula T. Hammond | 59 | 2020 | Independent Director |
Martin Kampmann | - | 2022 | Member of Scientific Advisory Board |
Thomas Christian Sudhof | 69 | - | Member of Scientific Advisory Board |
Peter Heutink | - | 2022 | Member of Scientific Advisory Board |
Errol De Souza | - | 2024 | Independent Director |
Mark Altmeyer | 63 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review